Search

Feminist translation is one of the key topics in current research and has developed by leaps and bounds since the 1980s. In order to correct the potential defects in feminist translation, some scholars put forward the translation perspective of androgyny. It was found that the translation studies of Gone with the Wind were mostly based on feminist translation strategies, but the research on translator’s ability of androgyny has still been insufficient. This paper used Gone with the Wind and its two Chinese translations as objects of the study. It compared different feminist translation strategies the two translators chose in their translations and evaluated whether these two translators have the ability of androgyny. After analyzing these cases, it was found that two translators all used feminist translation strategies to translate. They often used the strategy of “supplement”, and sometimes also used the strategy of “hijacking”, in order to strengthen the existence of female roles in the text. However, when translating characters whose genders were opposite to their own, the two translators failed to think from the perspective of these characters but translated literally or from the perspective of their own genders, which indicated that the perspective of androgyny was still difficult to achieve. Therefore, translators should be aware of the characteristics of two different genders and try to improve their ability of androgyny.

Purpose:TGFβs are overexpressed in many advanced cancers and promote cancer progression through mechanisms that include suppression of immunosurveillance. Multiple strategies to antagonize the TGFβ pathway are in early-phase oncology trials. However, TGFβs also have tumor-suppressive activities early in tumorigenesis, and the extent to which these might be retained in advanced disease has not been fully explored.Experimental Design:A panel of 12 immunocompetent mouse allograft models of metastatic breast cancer was tested for the effect of neutralizing anti-TGFβ antibodies on lung metastatic burden. Extensive correlative biology analyses were performed to assess potential predictive biomarkers and probe underlying mechanisms.Results:Heterogeneous responses to anti-TGFβ treatment were observed, with 5 of 12 models (42%) showing suppression of metastasis, 4 of 12 (33%) showing no response, and 3 of 12 (25%) showing an undesirable stimulation (up to 9-fold) of metastasis. Inhibition of metastasis was immune-dependent, whereas stimulation of metastasis was immune-independent and targeted the tumor cell compartment, potentially affecting the cancer stem cell. Thus, the integrated outcome of TGFβ antagonism depends on a complex balance between enhancing effective antitumor immunity and disrupting persistent tumor-suppressive effects of TGFβ on the tumor cell. Applying transcriptomic signatures derived from treatment-naïve mouse primary tumors to human breast cancer datasets suggested that patients with breast cancer with high-grade, estrogen receptor–negative disease are most likely to benefit from anti-TGFβ therapy.Conclusions:Contrary to dogma, tumor-suppressive responses to TGFβ are retained in some advanced metastatic tumors. Safe deployment of TGFβ antagonists in the clinic will require good predictive biomarkers.

Supplementary Materials and Methods and Supplementary Figures S1-S10